| Changes to trial information |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Trial Information |
Public title |
29/09/2025 |
Typographic error |
THE EFFECT OF COMPANIONSHIP IN LABOUR ON MATERNAL AND FETAL OUTCOMES AMONG PARTURIENTS AT JOS UNIVERSITY TEACHING HOSPITAL: A RANDOMISED CONTROLLED TRIAL |
The Effect of Companionship in Labor on Maternal and Fetal Outcome Among Parturient at Jos University Teaching Hospital: A Randomized Controlled Trial |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Trial Information |
Official scientific title |
29/09/2025 |
Typographic error |
THE EFFECT OF COMPANIONSHIP IN LABOUR ON MATERNAL AND FETAL OUTCOMES AMONG PARTURIENTS AT JOS UNIVERSITY TEACHING HOSPITAL: A RANDOMISED CONTROLLED TRIAL |
The Effect of Companionship in Labor on Maternal and Fetal Outcome Among Parturient at Jos University Teaching Hospital: A Randomized Controlled Trial |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Eligibility |
Age group |
29/09/2025 |
error during uploading |
Adult: 19 Year-44 Year |
Adolescent: 13 Year-18 Year, Adult: 19 Year-44 Year |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Intervention |
Intervention List |
29/09/2025 |
typographic error |
Control Group, doula support, , during active phase of labour, They received the routine care during labour , 80, Active-Treatment of Control Group |
Control Group, Did not receive doula support i.e routine intrapartum care, , during active phase of labour, They received the routine care during labour , 80, Active-Treatment of Control Group |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Ethics |
Ethics List |
30/09/2025 |
previous ethical clearance wasn't legible |
TRUE, JUTH Health Research Committe, lamingo, Jos, PMB 2076, Nigeria, , 11 Jun 2024, +2349030001194, info@juth.org.ng, 37137_34322_4737.pdf |
TRUE, JUTH Health Research Committe, lamingo, Jos, PMB 2076, Nigeria, , 11 Jun 2024, +2349030001194, info@juth.org.ng, 37137_34322_4737.pdf |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Funding Source |
FundingSources List |
29/09/2025 |
error in entering name of funding sources |
Self , Rayfield , Jos, , Nigeria, Self Funded, |
Dr. Mary Musa, Rayfield , Jos, , Nigeria, Self Funded, |
|
Section Name
|
Field Name
|
Date
|
Reason
|
Old Value
|
Updated Value
|
| Reporting |
IPD description |
29/09/2025 |
initial response wasn't correct |
A total of 174 women were assessed for eligibility, of which 160 met the inclusion criteria and were randomised equally into two groups: 80 received doula-supported care, and 80 received routine care. All participants in both groups received their allocated interventions. There were no losses to follow-up or exclusions from analysis, and data from all 160 participants were included in the final analysis.
The two groups were similar in their sociodemographic and obstetric characteristics,There was no significant difference in the age group distribution between the two groups (p = 0.670). Educational levels showed a marginal trend towards statistical significance, with more participants in the primary education category receiving doula care, although this was not significant overall (p = 0.056). Parity distribution did not differ significantly between groups (p = 0.338), and the median gestational age at delivery was 39.0 weeks (IQR = 2.0) in both groups (p = 0.374). Booking status and the onset of labour were also similar across groups, with no statistically significant differences noted (p = 0.620 and p = 0.719, respectively). The median cervical dilatation at admission was 6.0 cm in both groups (IQR = 1.0), with no significant difference (p = 0.622).
Labour and delivery outcomes are presented in Table 2. The median duration of the active phase of labour was 207.0 minutes (IQR = 174.5) in the doula care group and 195.0 minutes (IQR = 133.0) in the routine care group, with no significant difference (p = 0.231). |
The individual participant data (IPD) will be shared by widespread third party access to the IPD and associated documentation from the trial. The sharing shall be fully Open.
The following methods will be used;
* utilizing of data sharing platforms and repositories
* making data accessible through data sharing statements in clinical trial registries. |